Completed OBSERVATIONAL NCT02163473

Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

Sponsor: University of Florida

Conditions Sepsis

Interventions Healthy Control Septic patients

Updated 10 times since 2017 Last updated: Oct 12, 2016 Started: Jan 31, 2013 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02163473, this observational or N/A phase trial focuses on Sepsis and remains completed. Sponsored by University of Florida, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Florida

Data source: University of Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gainesville, United States